PT3018145T - Meios e métodos para tratar o dlbcl - Google Patents

Meios e métodos para tratar o dlbcl

Info

Publication number: PT3018145T
Authority: PT; Portugal
Prior art keywords: methods; treating dlbcl; dlbcl; treating
Prior art date: 2010-10-27

Application number

PT151950763T

Other languages

English (en)

Inventor

Zugmaier Gerhard

Nagorsen Dirk

Scheele Juergen

Original Assignee

Amgen Res Munich Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2011-10-27

Publication date

2018-05-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3018145(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-27 Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh

2018-05-17 Publication of PT3018145T publication Critical patent/PT3018145T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Carbon And Carbon Compounds (AREA)

PT151950763T 2010-10-27 2011-10-27 Meios e métodos para tratar o dlbcl PT3018145T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40710710P	2010-10-27	2010-10-27

Publications (1)

Publication Number	Publication Date
PT3018145T true PT3018145T (pt)	2018-05-17

Family

ID=45023802

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT181641754T PT3412687T (pt)	2010-10-27	2011-10-27	Métodos de tratamento de dlbcl
PT117876334T PT2632954E (pt)	2010-10-27	2011-10-27	Meios e métodos para tratar dlbcl
PT151950763T PT3018145T (pt)	2010-10-27	2011-10-27	Meios e métodos para tratar o dlbcl

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT181641754T PT3412687T (pt)	2010-10-27	2011-10-27	Métodos de tratamento de dlbcl
PT117876334T PT2632954E (pt)	2010-10-27	2011-10-27	Meios e métodos para tratar dlbcl

Country Status (31)

Country	Link
US (2)	US9192665B2 (pt)
EP (3)	EP3018145B1 (pt)
JP (3)	JP5997168B2 (pt)
KR (1)	KR101889995B1 (pt)
CN (2)	CN103459425B (pt)
AU (1)	AU2011322581B2 (pt)
CA (1)	CA2815119C (pt)
CL (1)	CL2013001138A1 (pt)
CR (1)	CR20130245A (pt)
CY (3)	CY1117155T1 (pt)
DK (3)	DK3018145T3 (pt)
EA (1)	EA032139B1 (pt)
ES (3)	ES2787044T3 (pt)
HR (2)	HRP20151444T4 (pt)
HU (3)	HUE027678T2 (pt)
IL (3)	IL225924A (pt)
LT (2)	LT3412687T (pt)
MA (1)	MA34619B1 (pt)
ME (1)	ME02311B (pt)
MY (1)	MY163057A (pt)
NZ (2)	NZ701715A (pt)
PH (1)	PH12013500826A1 (pt)
PL (3)	PL2632954T5 (pt)
PT (3)	PT3412687T (pt)
RS (3)	RS57260B1 (pt)
SG (1)	SG189869A1 (pt)
SI (3)	SI3018145T1 (pt)
SM (3)	SMT201800319T1 (pt)
TR (1)	TR201808019T4 (pt)
UA (1)	UA111175C2 (pt)
WO (1)	WO2012055961A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2417065T3 (es)	2005-04-26	2013-08-05	Trion Pharma Gmbh	Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
ES2787044T3 (es) *	2010-10-27	2020-10-14	Amgen Res Munich Gmbh	Métodos para tratar LDCBG
PL2637670T5 (pl) *	2010-11-10	2024-06-10	Amgen Research (Munich) Gmbh	Zapobieganie działaniom niepożądanym spowodowanym przez domeny wiążące specyficzne względem CD3
JO3529B1 (ar) *	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
JP6734774B2 (ja)	2013-10-15	2020-08-05	ザスクリプスリサーチインスティテュート	ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
WO2016154621A1 (en)	2015-03-26	2016-09-29	The California Institute For Biomedical Research	SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en)	2015-04-15	2016-10-20	The California Institute For Biomedical Research	Optimized pne-based chimeric receptor t cell switches and uses thereof
EA202090931A3 (ru)	2015-05-18	2020-10-30	Тср2 Терапьютикс Инк.	Композиции и способы перепрограммирования tcr с помощью гибридных белков
CA3001910A1 (en) *	2015-10-13	2017-04-20	Eureka Therapeutics, Inc.	Antibody agents specific for human cd19 and uses thereof
JP2019532017A (ja) *	2016-07-14	2019-11-07	フレッドハッチンソンキャンサーリサーチセンター	がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP7109789B2 (ja)	2016-08-02	2022-08-01	ティーシーアール２セラピューティクスインク．	融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN112280796A (zh)	2016-10-07	2021-01-29	T细胞受体治疗公司	使用融合蛋白进行t细胞受体重编程的组合物和方法
CA3040343A1 (en)	2016-10-19	2018-04-26	California Institute For Biomedical Research	Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3044593A1 (en)	2016-11-22	2018-05-31	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
JP2021508477A (ja)	2017-12-29	2021-03-11	オンコラス，インコーポレイテッド	治療用ポリペプチドの腫瘍溶解性ウイルス送達
WO2020099513A1 (en) *	2018-11-13	2020-05-22	Lipoxen Technologies Limited	Glycopolysialylation of blinatumomab
CN118593691A (zh) *	2019-05-03	2024-09-06	凯德药业股份有限公司	施用嵌合抗原受体免疫疗法的方法
KR20230031981A (ko)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113874398B (zh)	2019-05-21	2025-08-01	诺华股份有限公司	Cd19结合分子及其用途
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
IL303384A (en) *	2020-12-04	2023-08-01	Morphosys Ag	Anti-CD19 combination therapy
FI4284512T3 (fi)	2021-01-28	2025-05-22	Regeneron Pharma	Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
CA3247475A1 (en)	2022-04-11	2023-10-19	Regeneron Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
AU2024223918A1 (en)	2023-02-17	2025-09-11	Regeneron Pharmaceuticals, Inc.	Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3856559T2 (de)	1987-05-21	2004-04-29	Micromet Ag	Multifunktionelle Proteine mit vorbestimmter Zielsetzung
DE69909459T2 (de)	1998-04-21	2004-05-27	Micromet Ag	Cd19xcd3 spezifische polypeptide und deren verwendung
WO2004106381A1 (en)	2003-05-31	2004-12-09	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
ES2341252T3 (es)	2003-11-28	2010-06-17	Micromet Ag	Composiciones que comprenden polipeptidos.
KR101335798B1 (ko)	2005-02-15	2013-12-02	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
ES2417065T3 (es) *	2005-04-26	2013-08-05	Trion Pharma Gmbh	Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
AU2006326727A1 (en)	2005-12-16	2007-06-21	Amgen Research (Munich) Gmbh	Means and methods for the treatment of tumorous diseases
CN101331151A (zh) *	2005-12-16	2008-12-24	麦克罗梅特股份公司	治疗肿瘤性疾病的方式和方法
CA2662340C (en)	2006-09-08	2016-08-02	Medimmune, Llc	Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PT2520590T (pt)	2007-04-03	2018-11-14	Amgen Res Munich Gmbh	Domínio de ligação específico de espécies cruzadas
ES2727585T3 (es) *	2008-11-07	2019-10-17	Amgen Res Munich Gmbh	Tratamiento de leucemia linfoblástica aguda
HUE025759T2 (en) *	2009-10-27	2016-04-28	Amgen Res Munich Gmbh	Dosage regimen for administering a cd19xcd3 bispecific antibody
ES2787044T3 (es) *	2010-10-27	2020-10-14	Amgen Res Munich Gmbh	Métodos para tratar LDCBG

2011
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 SM SM20180319T patent/SMT201800319T1/it unknown
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active Active
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 SM SM20200232T patent/SMT202000232T1/it unknown
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 HR HRP20151444TT patent/HRP20151444T4/hr unknown
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 SI SI201131489T patent/SI3018145T1/en unknown
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en not_active Ceased
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 PH PH1/2013/500826A patent/PH12013500826A1/en unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en not_active Revoked
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown

Also Published As

Publication number	Publication date
NZ609201A (en)	2015-01-30
RS54525B2 (sr)	2021-08-31
RS60094B1 (sr)	2020-05-29
IL260774B (en)	2019-02-28
CA2815119C (en)	2023-01-10
EP3018145B1 (en)	2018-04-04
PL2632954T5 (pl)	2021-11-02
SMT201600050B (it)	2016-04-29
ES2787044T3 (es)	2020-10-14
SMT202000232T1 (it)	2020-07-08
HK1188229A1 (en)	2014-04-25
EA032139B1 (ru)	2019-04-30
US10696744B2 (en)	2020-06-30
JP2016164192A (ja)	2016-09-08
DK2632954T4 (da)	2021-08-09
SI2632954T1 (sl)	2016-02-29
CN103459425A (zh)	2013-12-18
HRP20151444T4 (hr)	2021-08-20
PT3412687T (pt)	2020-04-03
JP6522722B2 (ja)	2019-05-29
ES2563439T5 (es)	2022-02-04
EP3412687B1 (en)	2020-03-18
ME02311B (me)	2016-06-20
DK3018145T3 (en)	2018-05-28
ES2563439T3 (es)	2016-03-15
HUE027678T2 (en)	2016-11-28
JP2013540799A (ja)	2013-11-07
AU2011322581B2 (en)	2015-04-23
JP2018039838A (ja)	2018-03-15
SG189869A1 (en)	2013-06-28
SI3412687T1 (sl)	2020-07-31
ES2675299T3 (es)	2018-07-10
PL3018145T3 (pl)	2018-09-28
IL225924A0 (en)	2013-06-27
IL256110A (en)	2018-02-28
HRP20180882T1 (hr)	2018-07-27
CN103459425B (zh)	2015-11-25
US20130287778A1 (en)	2013-10-31
DK3412687T3 (da)	2020-05-11
NZ701715A (en)	2016-05-27
IL225924A (en)	2017-12-31
CA2815119A1 (en)	2012-05-03
SMT201800319T1 (it)	2018-07-17
CN105251003A (zh)	2016-01-20
AU2011322581A1 (en)	2013-05-09
CL2013001138A1 (es)	2014-11-14
RS54525B1 (sr)	2016-06-30
HRP20151444T1 (hr)	2016-01-29
SI2632954T2 (sl)	2021-11-30
KR20140019298A (ko)	2014-02-14
NZ719768A (en)	2021-07-30
PT2632954E (pt)	2016-02-03
EP2632954A1 (en)	2013-09-04
EP3018145A1 (en)	2016-05-11
LT3018145T (lt)	2018-05-10
JP6254220B2 (ja)	2017-12-27
WO2012055961A1 (en)	2012-05-03
DK2632954T3 (en)	2016-02-01
SI3018145T1 (en)	2018-08-31
EP3412687A1 (en)	2018-12-12
UA111175C2 (uk)	2016-04-11
MY163057A (en)	2017-08-15
EA201390387A1 (ru)	2013-10-30
IL256110B (en)	2018-08-30
PL2632954T3 (pl)	2016-05-31
KR101889995B1 (ko)	2018-08-20
CR20130245A (es)	2013-09-20
JP5997168B2 (ja)	2016-09-28
EP2632954B1 (en)	2015-11-25
LT3412687T (lt)	2020-07-27
US20160208001A1 (en)	2016-07-21
US9192665B2 (en)	2015-11-24
CY1117155T1 (el)	2017-04-05
MA34619B1 (fr)	2013-10-02
CY1120227T1 (el)	2018-12-12
PH12013500826A1 (en)	2013-06-17
CN105251003B (zh)	2019-08-02
EP2632954B2 (en)	2021-07-07
HUE048639T2 (hu)	2020-08-28
HUE037786T2 (hu)	2018-09-28
TR201808019T4 (tr)	2018-06-21
RS57260B1 (sr)	2018-08-31
PL3412687T3 (pl)	2020-07-27
CY1123251T1 (el)	2021-10-29

Publication	Publication Date	Title
HRP20180882T1 (hr)	2018-07-27	Sredstva za i postupci liječenja dlbcl
AP3269A (en)	2015-05-31	Methods and compounds for treating paramyxoviridaevirus infections
PL2649391T3 (pl)	2017-10-31	Urządzenie do suszenia i sposoby suszenia
ZA201303423B (en)	2015-06-24	Compositions and methods for treating myelofibrosis
GB201003190D0 (en)	2010-04-14	Apparatus and method
PL2525953T3 (pl)	2014-05-30	Sposób i urządzenie do obróbki i odkażania
ZA201304360B (en)	2014-02-26	Method and device for treating biomass
EP2712445A4 (en)	2015-04-22	METHOD AND APPARATUS FOR ZONE REDUCTION AND / OR MEMORY POWER SUPPLY
GB201002083D0 (en)	2010-03-24	Apparatus for improving and/or maintaining numerical ability
GB2483684B (en)	2014-05-07	Range determination apparatus and method
GB201005885D0 (en)	2010-05-26	Apparatus and method
PT2627818T (pt)	2021-04-07	Método e disposição para tratamento de pasta
GB201003255D0 (en)	2010-04-14	Apparatus and method
GB201105826D0 (en)	2011-05-18	Apparatus and method
GB201021057D0 (en)	2011-01-26	Method and apparatus
GB201006393D0 (en)	2010-06-02	An apparatus and associated methods
GB201011768D0 (en)	2010-08-25	Apparatus and methods for operation
GB201000806D0 (en)	2010-03-03	Apparatus and methods
GB201010290D0 (en)	2010-08-04	Apparatus and methods
GB201008082D0 (en)	2010-06-30	Apparatus and method
GB201003264D0 (en)	2010-04-14	Apparatus and method
GB201001033D0 (en)	2010-03-10	Method and apparatus
GB201016993D0 (en)	2010-11-24	Apparatus and method
GB201010267D0 (en)	2010-08-04	Apparatus and method
GB201001459D0 (en)	2010-03-17	Apparatus and method